Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3047117 | 0.89 | PLA2G7 (0.48) | PLA2G7ALOX12PKMADORA2ACYP2C19 | |
| SCHEMBL3038079 | 0.81 | PLA2G7 (0.65) | PLA2G7PKMADORA2ACYP2C19MEN1 | |
| SCHEMBL3643754 | 0.80 | PLA2G7 (0.47) | PLA2G7PKMADORA2ACYP2C19TDP1 | |
| SCHEMBL3044208 | 0.78 | MAPT (0.52) | PLA2G7ALOX12CYP2C19MEN1KMT2A | |
| SCHEMBL3048427 | 0.77 | PLA2G7 (0.50) | PLA2G7PKMADORA2ATDP1MEN1 | |
| SCHEMBL3049191 | 0.77 | SMN1; SMN2 (0.53) | PLA2G7ALOX12PKMTDP1MEN1 | |
| SCHEMBL3047436 | 0.76 | PLA2G7 (0.42) | PLA2G7ALOX12PKMTDP1MEN1 | |
| SCHEMBL3038930 | 0.74 | PLA2G7 (0.47) | PLA2G7MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13548282 | 0.74 | PLA2G7 (0.52) | PLA2G7MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3053636 | 0.73 | SYK (0.54) | PLA2G7ALOX12PKMCYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018209-B2 | Compounds and methods for the treatment of viruses and cancer | YALE UNIVERSITY (US) | 2015-04-28 | — | — | US | claimed |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | YALE UNIVERSITY (US) | 2010-09-02 | — | — | US | claimed |
| WO-2007038387-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER | YALE UNIVERSITY (US) | 2007-04-05 | — | — | WO | claimed |
| US-9018209-B2 | Compounds and methods for the treatment of viruses and cancer | YALE UNIVERSITY (US) | 2015-04-28 | — | — | US | disclosed |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | YALE UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2007038387-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER | YALE UNIVERSITY (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | RCOR1, RCOR3, CCNT1 | PLA2G7 4400/4885ALOX12 731/4885PKM 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.